摘要
Objective To investigate the long term efficacy and side effects of a donor-derived CD19 chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζCAR-T) therapy in the treatment of patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
作者
MA Runzhi
马润芝(State Key Lab,Hematol Experiment,Natl Clin Blood Dis Res Center,Instit Hemat&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020)